Survey of Ophthalmology
Volume 44 , Pages S141-S145 , January 2000

Ocular Comfort of Brinzolamide 1.0% Ophthalmic Suspension Compared With Dorzolamide 2.0% Ophthalmic Solution: Results From Two Multicenter Comfort Studies

  • Lewis H Silver, PhD

      Affiliations

    • Alcon Research, Ltd., Fort Worth, TX, USA
    • Corresponding Author InformationReprint address: Lewis H. Silver, PhD, Senior Director, Clinical Science, Ophthalmic Products, Alcon Laboratories, Inc., 6201 South Freeway, R5-10, Fort Worth, TX 76134-2099
    • ,
  • the Brinzolamide Comfort Study Group

      Affiliations

    • Alcon Research, Ltd., Fort Worth, TX, USA

References 

  1. Bouomi L, Bucci MG. In: The epidemiology of glaucoma and groups at risk. Chibret International: Diagnosis and management of early glaucoma; practical concepts and future trends. December 6–7: 1984; Rome Italy. Chibret Int J Ophthalmol Suppl 1985;p. 6–15
  2. Camras C, Brinzolamide Primary Therapy Study Group . A triple-masked, primary therapy study of the efficacy and safety of bid- and tid-dosed brinzolamide 1% compared to tid-dosed dorzolamide 2% and bid-dosed timolol 0.5% (abstract). Invest Ophthalmol Vis Sci. 1997;38(suppl 4):S560
  3. Dean T, May J, Chen HH, et al.  Brinzolamide (AL-4862) suspension is a new topically active carbonic anhydrase inhibitor in the Dutch-belted rabbit and cynomolgus monkey (abstract). Invest Ophthalmol Vis Sci. 1997;38(suppl 4):S813
  4. Hurvitz LM, Kaufman PL, Robin AL, et al.  New developments in the drug treatment of glaucoma. Drugs. 1991;41:514–532
  5. Laibovitz R, Boyle J, Snyder E, et al.  Dorzolamide versus pilocarpine as adjunctive therapies to timolol (a comparison of patient preference and impact on daily life). Clin Ther. 1996;18:821–832
  6. March W, Silver L, Brinzolamide Long-Term Therapy Study Group . The long-term safety and efficacy of brinzolamide (Azopt®), a new topical carbonic anhydrase inhibitor, in patients with open angle glaucoma and ocular hypertension (abstract). Invest Ophthalmol Vis Sci. 1998;39(suppl 4):S199
  7. Sall K, Brinzolamide Primary Therapy Study Group . The efficacy and safety of brinzolamide 1% ophthalmic suspension (Azopt®) as a primary therapy in patients with primary open-angle glaucoma or ocular hypertension. Surv Ophthalmol. 2000;44(suppl 2):S155–S162
  8. Silver L, Brinzolamide Primary Therapy Study Group . Clinical efficacy and safety of brinzolamide (Azopt®), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol. 1998;126:400–408
  9. Stewart R, Brinzolamide Comfort Study Group . The ocular comfort of tid-dosed brinzolamide 1.0% compared to tid-dosed dorzolamide 2.0% in patients with primary open-angle glaucoma or ocular hypertension (abstract). Invest Ophthalmol Vis Sci. 1997;38(suppl 4):S559
  10. Strahlman E, Tipping R, Vogel R, Dorzolamide Dose-Response Study Group . A 6-week dose-response study of the ocular hypotensive effect of dorzolamide with a one-year extension. Am J Ophthalmol. 1996;122:183–194
  11. Stralhlman ER, Vogel R, Tiping R, Clineschmidt CM, Dorzolamide Additivity Study Group . The use of dorzolamide and pilocarpine as adjunctive therapy to timolol in patients with elevated intraocular pressure. Ophthalmology. 1996;103:1283–1293
  12. Vaughan D, Riordan-Eva P. Glaucoma, in Vaughan D, Asbury T, Riordan-Eva P (eds): General Ophthalmology. Norwalk, CT, Appleton & Lange, 1992, pp 213–30

☆ Dr. Silver is employed by Alcon Research, Ltd.

PII: S0039-6257(99)00111-3

Survey of Ophthalmology
Volume 44 , Pages S141-S145 , January 2000

Article Tools

* Image Usage & Resolution